Search Results
Feb 13, 2026, 11:47 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN UPLIZNA ® ДЛЯ ЛЕЧЕНИЯ ГЕНЕРАЛИЗОВАННОЙ МИАСТЕНИИ
https://www.ema.europa.eu/en/news/first-treatment-recommended-rare-immunoglobulin-related-autoimmune-disease. Доступно: февраль 2026 года.Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for
More news about: Amgen
Feb 13, 2026, 11:41 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK UPLIZNA® SPOLEČNOSTI AMGEN PRO GENERALIZOVANOU MYASTENII GRAVIS
gravis. N Engl J Med. (2025) 392 / (23) 2309-2320Evropská agentura pro léčivé přípravky. First treatment recommended for rare immunoglobulin-related autoimmune disease. K dispozici na
More news about: Amgen
Feb 13, 2026, 11:30 ET Trinitē Road Rally Launches 500-Mile Adventure Motorsport Event
the rally is to celebrate all vehicles and create an egalitarian space within the rally world that welcomes the vehicles in our driveways, not just rare, vintage, or specific brands.The competition is focused on precision driving and navigation, not fastest speed. Participants will experience carefully
More news about: Trinitē Road Rally
Feb 13, 2026, 11:00 ET Brandon McMillan to Appear Live at Global Pet Expo with Exclusive Training Demonstration and Highly Anticipated Product Launch
to pet parents for the first time. Select attendees may even have the opportunity to see their own dogs work with McMillan live on stage, offering a rare, interactive look at elite training techniques in action. This debut marks the first public introduction of a training collection personally designed,
More news about: American Pet Products Association, Inc.
Feb 13, 2026, 11:00 ET Open Pontoon Boat Market Poised for Steady Expansion from USD 1.5 Billion in 2024 to USD 2.3 Billion by 2033, Supported by Rising Recreational Boating Demand : - Market Research Intellect
(Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular and Genetic Disorders), Insights, Growth
More news about: Market Research Intellect
Feb 13, 2026, 10:39 ET Electronic Discovery Software Market to Reach USD 10.1 Billion by 2033, Fueled by Rising Digital Litigation, Regulatory Compliance Needs, and Advanced Analytics Adoption: Market Research Intellect
(Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular and Genetic Disorders), Insights, Growth
More news about: Market Research Intellect
Feb 13, 2026, 10:05 ET National Wine Day Turns 25: The Republic of Moldova - A Small Country with Global Wine Ambitions
places in the world celebrate wine as a defining element of national identity through an annual national holiday. The Republic of Moldova is among these rare destinations. In 2026, National Wine Day - the country's flagship wine celebration and one of Europe's Top 10 open-air events - marks its 25th anniversary,
More news about: The National Office for Vine and Wine, (Republic of Moldova)
Feb 13, 2026, 09:59 ET National Wine Day Turns 25: The Republic of Moldova - A Small Country with Global Wine Ambitions
places in the world celebrate wine as a defining element of national identity through an annual national holiday. The Republic of Moldova is among these rare destinations. In 2026, National Wine Day - the country's flagship wine celebration and one of Europe's Top 10 open-air events - marks its 25th anniversary,
More news about: The National Office for Vine and Wine, (Republic of Moldova)
Feb 13, 2026, 09:59 ET WORLD PREMIERE OF UNIVERSAL THEME PARKS: THE EXHIBITION OPENS AT THE FRANKLIN INSTITUTE ON FEBRUARY 14
and with Nintendo's iconic Super Mario™ ? Block. Video shorts featuring storyboard artists, lighting designers, prop masters, and others will offer a rare glimpse into the universe of innovation driven by the creative forces that push the boundaries of themed entertainment."The themed entertainment
More news about: The Franklin Institute
Feb 13, 2026, 09:34 ET KOMISJA EUROPEJSKA ZATWIERDZA LEK UPLIZNA® FIRMY AMGEN W LECZENIU UOGÓLNIONEJ MIASTENII
inebilizumabu w uogólnionej miastenii). N Engl J Med. 2025;392(23):2309-2320.European Medicines Agency. First treatment recommended for rare immunoglobulin-related autoimmune disease (Pierwsza terapia rekomendowana w rzadkiej autoimmunologicznej chorobie związanej z immunoglobuliną). Źródło:
More news about: Amgen
Feb 13, 2026, 08:32 ET The Boston Globe to Host Rare Disease Summit
2026 /PRNewswire/ -- The Boston Globe is proud to convene the rare disease community at the second annual Rare Disease Summit on February 24, at 9:30 a.m. ET. Bringing together the individuals and the companies driving innovation in the rare disease space, this Summit will feature special keynote remarks,
More news about: Boston Globe Media
Feb 13, 2026, 08:00 ET Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
formulary review efforts are progressing as planned. We are preparing to expand our field presence to support a highly concentrated prescriber base in this rare cancer setting, supported by an advanced AI-enabled commercial platform designed to drive efficient market penetration," added Mazur."As LYMPHIR
More news about: Citius Oncology, Inc.
Feb 13, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
an AI-enabled commercial platform to support targeted physician engagement and efficient penetration of a highly concentrated prescriber base in this rare oncology market;International patient access advancing: Agreements have been negotiated with regional partners to enable patient access
More news about: Citius Pharmaceuticals, Inc.
Feb 13, 2026, 07:37 ET ICONIC FLORIDA POLO FACILITY HITS THE MARKET
is also comparable in size.Valiente Farm, on every level - privacy, tranquility, flexibility, and ambience stands apart. Truly One of One. A rare opportunity for new stewards to continue their own vision and build upon one of the greatest dreams ever realized in sport.About Valiente
More news about: Icon Global Group, LLC
Feb 13, 2026, 07:37 ET ICONIC FLORIDA POLO FACILITY HITS THE MARKET
is also comparable in size.Valiente Farm, on every level - privacy, tranquility, flexibility, and ambience stands apart. Truly One of One. A rare opportunity for new stewards to continue their own vision and build upon one of the greatest dreams ever realized in sport.About Valiente
More news about: Icon Global Group, LLC
Feb 13, 2026, 06:30 ET Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
Sclerosis, and Transition into a Commercial Organization –– Simona Skerjanec, Former SVP, Global Head of Neuroscience and Rare Diseases at Roche, Elevated to Interim Chairperson of the Board of Directors –– Thor Nagel, Principal at BVF Partners L.P.,
More news about: Immunic, Inc.
Feb 13, 2026, 04:00 ET Gaotu Techedu to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 5, 2026
and drive continuous growth. The Company provides AI-powered, product-led learning solutions for learners from pre-school to adulthood. By combining rare, high-caliber teaching resources with AI-enhanced tools and content, Gaotu creates engaging and effective learning experiences delivered through both
More news about: Gaotu Techedu Inc.
Feb 13, 2026, 01:04 ET HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
multinational partners as we explore collaboration and licensing opportunities for HCB101 and our broader immunotherapy pipeline."Gastric cancer is a rare disease in the United States, with prevalence well below the FDA's statutory threshold for orphan designation. Despite advances in targeted therapy
More news about: HanchorBio Inc.
Feb 12, 2026, 18:42 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected]
More news about: Pomerantz LLP
Feb 12, 2026, 18:42 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR
phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." The press release said that "[t]he FDA raised an issue with the potential for underexposure in lower weight pediatric patients.
More news about: Pomerantz LLP
Feb 12, 2026, 17:00 ET PTC Therapeutics Provides Regulatory Update on Translarna™
functional, such as dystrophin in Duchenne.About Duchenne Muscular Dystrophy (Duchenne)Primarily affecting males, Duchenne is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-20s due to heart
More news about: PTC Therapeutics, Inc.
Feb 12, 2026, 16:05 ET BioMarin Announces Closing of Private Offering of Senior Notes
transfer of securities in any jurisdiction in contravention of applicable law.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael,
More news about: BioMarin Pharmaceutical Inc.
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for purported optimal effect.Inovio's lead product candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis ("RRP"), a life-long, rare disease of the respiratory tract caused by HPV infection. At all relevant times, Defendants touted the prospects of the U.S. Food and Drug Administration
More news about: Pomerantz LLP
Feb 12, 2026, 15:30 ET LA COMMISSION EUROPEENNE APPROUVE UPLIZNA® D'AMGEN DANS LE CADRE DU TRAITEMENT DE LA MYASTHÉNIE GRAVE GÉNÉRALISÉE
dosage d'entretien deux fois par an, après deux doses de charge initiales. La myasthénie généralisée grave est une maladie auto-immune chronique, rare et imprévisible, à médiation cellulaire B, qui provoque une faiblesse musculaire fluctuante et peut avoir un impact sur la qualité de vie.1-3 Il
More news about: Amgen
Feb 12, 2026, 15:15 ET La Comisión Europea aprueba UPLIZNA® de Amgen para la miastenia gravis generalizada
https://www.ema.europa.eu/en/news/first-treatment-recommended-rare-immunoglobulin-related-autoimmune-disease. Consultado: febrero de 2026.Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for
More news about: Amgen